UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features

Annals of oncology, 2014-10, Vol.25 (10), p.1995-2001

2014

Volltextzugriff (PDF)

Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity

Nature communications, 2021-07, Vol.12 (1), p.4117-4117, Article 4117

2021

Volltextzugriff (PDF)

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

Annals of oncology, 2018-11, Vol.29 (11), p.2240-2246

2018

Volltextzugriff (PDF)

Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study

Annals of oncology, 2017-05, Vol.28 (5), p.1023-1031

2017

Volltextzugriff (PDF)

Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial

Annals of oncology, 2015-01, Vol.26 (1), p.126-132

2015

Volltextzugriff (PDF)

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

Annals of oncology, 2019-11, Vol.30 (11), p.1796-1803

2019

Volltextzugriff (PDF)

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer

European journal of cancer (1990), 2015-07, Vol.51 (10), p.1243-1252

2015

Volltextzugriff (PDF)

Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer

JNCI : Journal of the National Cancer Institute, 2012-11, Vol.104 (21), p.1635-1646

2012

Volltextzugriff (PDF)

Guidelines for the clinical management of familial adenomatous polyposis (FAP)

Gut, 2008-05, Vol.57 (5), p.704-713

2008

Volltextzugriff (PDF)

PG 2.04 Systemic treatment of CRC: Molecular profiles ready for clinical practice?

European journal of cancer (1990), 2012-03, Vol.48, p.S3-S3

Tejpar, S

2012

Volltextzugriff (PDF)

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

Annals of oncology, 2008-03, Vol.19 (3), p.508-515

2008

Volltextzugriff (PDF)

Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis

British journal of cancer, 2015-07, Vol.113 (3), p.500-509

2015

Volltextzugriff (PDF)

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

British journal of cancer, 2013-02, Vol.108 (3), p.668-675

2013

Volltextzugriff (PDF)

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program

Virchows Archiv : an international journal of pathology, 2008-11, Vol.453 (5), p.417-431

2008

Volltextzugriff (PDF)

Peutz–Jeghers syndrome: a systematic review and recommendations for management

Gut, 2010-07, Vol.59 (7), p.975-986

2010

Volltextzugriff (PDF)

Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe

Annals of oncology, 2022-11, Vol.33 (11), p.1200-1202

2022

Volltextzugriff (PDF)

Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel

Annals of oncology, 2020-08, Vol.31 (8), p.1021-1029

2020

Volltextzugriff (PDF)

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

British journal of cancer, 2015-06, Vol.112 (12), p.1874-1881

2015

Volltextzugriff (PDF)

Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)

Annals of oncology, 2009-08, Vol.20 (8), p.1375-1382

2009

Volltextzugriff (PDF)

Prevalence of microsatellite instable and Epstein-Barr Virus-driven gastro- esophageal cancer in a large Belgian cohort

Acta gastro-enterologica belgica, 2022-01, Vol.85 (1), p.1-5

2022

Volltextzugriff (PDF)

A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design

Seminars in cancer biology, 2018-10, Vol.52 (Pt 2), p.158-165

2018

Volltextzugriff (PDF)

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study

ESMO open, 2023-12, Vol.8 (6), p.102041-102041, Article 102041

2023

Volltextzugriff (PDF)

Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy

Annals of oncology, 2019-07, Vol.30, p.iv133-iv133

2019

Volltextzugriff (PDF)

Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)

Annals of oncology, 2018-10, Vol.29, p.viii640-viii640

2018

Volltextzugriff (PDF)

1 – 25 von 483

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(458)
Mit Volltextzugriff
(422)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(250)
Life Sciences & Biomedicine
(235)
Humans
(210)
Oncology
(148)
Colorectal Cancer
(94)
Tumors
(94)
Female
(86)
Male
(82)
Mutation
(74)
Colorectal Neoplasms - Genetics
(72)
Middle Aged
(70)
Aged
(61)
Biological And Medical Sciences
(60)
Colorectal Neoplasms - Drug Therapy
(57)
Medical Sciences
(57)
Colorectal Neoplasms - Pathology
(54)
Adult
(53)
Prognosis
(46)
Cancer
(42)
Cetuximab
(39)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features

Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study

Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer

Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer

Guidelines for the clinical management of familial adenomatous polyposis (FAP)

PG 2.04 Systemic treatment of CRC: Molecular profiles ready for clinical practice?

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program

Peutz–Jeghers syndrome: a systematic review and recommendations for management

Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe

Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)

Prevalence of microsatellite instable and Epstein-Barr Virus-driven gastro- esophageal cancer in a large Belgian cohort

A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study

Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy

Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)

Suchergebnisse filtern